<DOC>
	<DOCNO>NCT01285544</DOCNO>
	<brief_summary>There significant difference efficacy tolerability test reference formulation atorvastatin 20 mg Korean adult primary hypercholesterolemia .</brief_summary>
	<brief_title>The Efficacy Tolerability Two Formulations Atorvastatin In Korean Adult With Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>patient age 20 79 year primary hypercholesterolemia sufficiently responsive therapeutic lifestyle change LDLC level 100 mg/dL high risk group . Inclusion criterion accordance drug treatment guideline ; coronary artery disease equivalent group LDLC ≥100 mg/dl ; patient two risk factor LDLC≥130 mg/dl ; patient 0 1 risk factor LDLC &gt; 160 mg/dl therapeutic lifestyle change therapy investigational drug within 30 day randomization , history hypersensitivity HMGCoA reductase inhibitor , uncontrolled hypertension , poorly control diabetes ( glycosylated hemoglobin [ HbA1c ] &gt; 9 % ) , unstable angina present newonset myocardial infarction ( within 6 month ) , creatinine &gt; 2.5 mg/dl , alanine aminotransferase ( ALT ) &gt; 2 x upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) &gt; 2 x ULN , creatine kinase ( CK ) &gt; 2 x ULN , history malignancy psychosis ; chronic liver disease , drug alcohol abuse , pregnancy , breastfeeding , failure practice adequate contraception , cyclical hormonal contraceptive intermittent use hormone replacement therapy .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>statin</keyword>
	<keyword>cholesterol</keyword>
	<keyword>hypercholesterolemia</keyword>
	<keyword>atorvastatin</keyword>
	<keyword>Dyslipidemia cardiovascular disease ( KoLipinon )</keyword>
</DOC>